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of respondents were female (70%), with an average age of 50.6
years and incomes < $40,000 (n = 70). Preference scores for
HUI3, EQ5D and EQVAS were 0.62, 0.64, and 0.66 respectively.
Average score for AQLQ was 4.46 and for norm based PCS, and
MCS, 40.07 and 46.94, respectively. Patients reported to be WTP
US$89 and US$62 per month for an asthma cure and treatment,
respectively. Pearson r correlations between generic HRQOL
instruments (HUI3, EQ5D and EQVAS) and AQLQ were mod-
erate to high in the predicted direction (r = 0.434 to 0.689, p <
0.01). PCS and MCS scores correlated moderately with prefer-
ence based measures (r = 0.306 to 0.628, p < 0.05). WTP for an
asthma treatment was moderately correlated with AQLQ and its
dimensions (p < 0.05). CONCLUSION: Study ﬁndings show a
preference based disease speciﬁc measure was a better predictor
of WTP than a non preference based metric. This can be
explained by additional sensitivity of a disease speciﬁc measure
and the underlying utility framework purported to underlie WTP
and utility measures.
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OBJECTIVE: To estimate which (input) factors inﬂuence
patients’ satisfaction of asthma treatment and what impact each
factor has on the overall satisfaction. A secondary objective is to
look how outcome variables, as compliance/adherence and
health-related quality of life (HRQL), and are connected with
the overall satisfaction. METHODS: To be able to estimate
which factors that are determining patient satisfaction with
asthma treatment a questionnaire regarding features of the drug,
the physician, the nurse, the availability of the centre, compli-
ance, and health related quality of life was administrated. A total
of 599 patients with asthma, aged 18–65 years, from 17 centres
in Sweden completed the questionnaire. A Patient Satisfaction
Index (PSI) was estimated and each factors impact on the overall
satisfaction was analysed. The statistical technique applied for
this analysis was Partial Least Squares (PLS), which is well suited
for structural equation modelling when the focus is on identify-
ing the most important characteristics. RESULTS: The two most
important factors for the patients’ overall satisfaction (PSI) of
asthma treatment are the drug and the physician (both have a
regression coefﬁcient of 1.7). The nurse and the availability of
the health centre are, although statistically signiﬁcant, of less
importance. The most important factor for compliance is the
drug, where the ease of usage, and absence of side effect was 
estimated having a higher impact for compliance then the price
and the effect of the drug. However, it is interesting to 
note despite showing a high PSI patients’ still state low HRQL.
CONCLUSIONS: The most important factors in the treatment
of asthma from the patients point of view are the drug and 
the physician.
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OBJECTIVE: Preference scores are needed for cost-effectiveness
analyses that are particularly important for assessing expensive
technologies such as intensive care therapies for ARDS patients.
Preference data for ARDS patients can be generated using sec-
ondary analysis of descriptive HRQOL data, but it is not known
which preference algorithm is to be preferred. Our objective was
to compare two methods for deriving preference scores of ARDS
survivors from SF-36 scores, one Quality of Well-Being based—
Fryback et al.(1997) and the other Health Utilities Index based-
Nichol et al. (2002) with directly rated Visual Analogue Scale
(VAS) preference. Agreement between these approaches and their
validity relative to other HRQOL measures were examined.
METHODS: Data were collected from 43 ARDS survivors iden-
tiﬁed from three major hospitals in Twin Cities, Minnesota, from
1993 to 2001. The questionnaire included the VAS, the SF-36,
Center for Epidemiologic Studies-Depression, life satisfaction
and happiness, and Karnofsky Performance Index. Repeated
measures ANOVA and post-hoc t-tests were used to analyze dif-
ferences among preference scores. The intra-class correlation
coefﬁcient (ICC) was employed to assess agreement between the
two scores. Spearman rank correlation coefﬁcients (r) were used
to measure the correlation between these preferences and other
health outcomes. RESULTS: The mean (SD) preference scores
were 0.603 (0.24), 0.632 (0.09), and 0.679 (0.18) for VAS,
Fryback and Nichol methods, respectively. The agreement for
VAS & Nichol was higher than that for Fryback & Nichol with
ICCs of 0.7744 and 0.7247, respectively. Agreement for VAS &
Fryback was poor with ICC of 0.4895. The Fryback score
showed poor correlation with SF-36 Mental Component
Summary score, life satisfaction and happiness (r < 0.40); the
Nichol and VAS preferences had higher correlations with these
measures. CONCLUSIONS: Choice of preference algorithm
impacts both the mean preference and its validity. In ARDS, the
Nichol approach may be preferred.
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OBJECTIVES: Anemia is a common hematological disorder
characterized by reduced hemoglobin concentration due to
various causes. Conservative estimates suggest that 3.4 million
individuals in the US are anemic (National Center for Health 
Statistics). Despite data on anemia prevalence and associated
outcomes, little is known about the impact of anemia on health
care utilization and costs. The National Anemia Action Council
initiated this study to examine medical costs associated with
anemia. METHODS: The study used retrospective administra-
tive claims data (facility, professional, outpatient pharmacy)
from MEDSTAT Group’s MarketScan Databases for patients
newly diagnosed with anemia, including up to 12 months follow
up. Predisposing conditions were identiﬁed using ICD-9-CM
diagnosis codes for chronic kidney disease (CKD), human
immunodeﬁciency virus (HIV), rheumatoid arthritis (RA),
inﬂammatory bowel disease (IBD), congestive heart failure
(CHF), and solid tumor cancers. Descriptive analyses compared
costs between anemic patients and a random sample of non-
